Clinical impact of rebiopsy among patients with epidermal growth factor receptor‐mutant lung adenocarcinoma in a real‐world clinical setting
| Autor: | Yunha Nam, Ho Cheol Kim, Young‐Chul Kim, Seung Hun Jang, Kye Young Lee, Shin Yup Lee, Sang Hoon Lee, Sung Yong Lee, Seong Hoon Yoon, Jeong‐Seon Ryu, Tae Won Jang, Yoon Soo Chang, Seung Joon Kim, Chan Kwon Park, Jeong Eun Lee, Chi Young Jung, Chang‐Min Choi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Thoracic Cancer, Vol 12, Iss 6, Pp 890-898 (2021) |
| Druh dokumentu: | article |
| ISSN: | 1759-7714 1759-7706 |
| DOI: | 10.1111/1759-7714.13857 |
| Popis: | Abstract Background In this study, we investigated the risk factors of acquired T790M mutation among patients with lung adenocarcinoma with epidermal growth factor receptor (EGFR) tyrosine mutation who were treated with EGFR‐tyrosine kinase inhibitors (TKIs). The aim was to identify the clinical impact of rebiopsy. Methods This multicenter, retrospective cohort study was conducted in South Korea from January 2007 to June 2017. Patients with adenocarcinoma with EGFR mutation who underwent rebiopsy and were treated with EGFR‐TKIs were included. Results Of a total of 352 patients, T790M mutation was identified in 156 (41.9%) at the time of rebiopsy. The median duration from initial biopsy to rebiopsy was 17 months. Univariate logistic regression analysis revealed associations of exon 19 deletion (odds ratio [OR], 1.643; p = 0.026), absence of L858R (OR, 0.627; p = 0.042), and previous EGFR‐TKI treatment duration (OR, 1.039; p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|